Selection of Pre-Fillable Syringes When Developing a Vaccine 2021 - Stevanato Group
search img
Selection of Pre-Fillable Syringes When Developing a Vaccine 2021 - Stevanato Group
Home - Integrated solutions for pharma & healthcare - Stevanato Group > News & Events - Stevanato Group > Webinars - Stevanato Group > Selection of Pre-Fillable Syringes When Developing a Vaccine 2021 - Stevanato Group
page-wrapper
WEBINAR

Early-Stage Considerations for the Selection of
Pre-Fillable Syringes When Developing a Vaccine

13 May 2021

Stevanato Group will present a webinar on:

Early-Stage Considerations for the Selection of Pre-Fillable Syringes When Developing a Vaccine

Webinar Details:

  • Date: Thursday, May 13th 
  • Time: 11.00 am EDT / 5.00 pm CET
  • Duration: 1 hour with live Q&A
  • Language: English

 

ITC Webinar - website graphic
ITC Webinar - website graphic

Complete today the registration form to reserve your seat for our webinar!

Webinar abstract:

Today, most of the COVID-19 vaccine containers are vials, thanks to their flexibility in the drug development phase and their possibility of delivering multi-doses with a single container.

However, even without considering the impact of COVID-19, the demand for vaccines in syringes is expected to grow. Due to the several benefits, such as reducing medical dosing errors, minimizing the risk of contamination by the ease of use, and reducing waste of drug products, syringes will represent a win-win scenario for end-users and manufacturers.

When converting from a vial delivery method to a pre-fillable syringe, we need to consider several factors: indeed, every vaccine has unique features requiring different packaging characteristics in terms of sensitivity to temperature, the scale of manufacture, and delivery technology.

In this webinar, we will provide an overview of the strategy to speed up the migration from a vial to a pre-fillable syringe to address all these aspects. We will then discuss the different packaging characteristics, assess the syringe platform, and present what Stevanato Group can offer to support pharma partners in delivering a safe and effective vaccine.

Key Learning Objectives:

This presentation aims to show the main considerations in meeting and overcoming PFS-drug challenges when developing a vaccine.

Specifically, the focus is to illustrate:

  • why selecting a syringe for the vaccine program
  • what needs to be considered when choosing a syringe container
  • which are the available and suggested options offered in the market
  • which are the complementary aspects to be included to make a safe and informed decision

Who Should Attend:

Recommended attendees include those who are:

Professionals involved in, development, and manufacturing of biopharmaceuticals, primary drug container and parenteral drug device development like:

  • Primary Container Engineers
  • Device Engineers
  • Quality Engineer
  • Operations Specialists

About the speaker:

Enrico Barichello Photo
Enrico Barichello Photo

Enrico Barichello

Product Manager, Stevanato Group

With a background in Industrial Engineering and a Master’s in Management at the University of Padua, Enrico Barichello acquired broad-spectrum skills in technical concepts and complex processes.

He joined Stevanato Group in 2017 as a Product Management Specialist for syringe platform. He defined and coordinated all the activities required to bring the products to market, bridging gaps between different company functions and aligning the involved teams.

From January 2021, he is the product owner, responsible for the roadmap and execution of the new innovative platform SG Alba®.